Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib vs TACE in Advanced HCC With Portal Vein Invasion
NCT01480817Phase 2Terminated
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2012
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by Seoul National University Hospital. Started Jun 2012; status: terminated.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01480817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01480817.